HR5448

The 'Protecting Free Vaccines Act' has been referred to key committees, indicating it is in the early stages of the legislative process. This bill's objective is to ensure vaccines remain free for the public, which directly affects the financial landscape for vaccine manufacturers. Currently, many vaccines are covered by federal programs or insurance, and this bill seeks to solidify that framework, potentially expanding federal responsibility for vaccine costs. Historically, federal funding for vaccine procurement has been a significant revenue stream for pharmaceutical companies. During the COVID-19 pandemic, the U.S. government purchased billions of dollars worth of vaccines directly from manufacturers. For example, in 2020 and 2021, the U.S. government committed over $10 billion to Pfizer ($PFE) and BioNTech ($BNTX) for COVID-19 vaccine doses. Moderna ($MRNA) also received substantial government contracts. This bill, by codifying free access, ensures continued government involvement in vaccine financing, which translates to sustained demand and revenue for these companies. When the CARES Act was passed in March 2020, which included significant funding for vaccine development and procurement, pharmaceutical companies involved in vaccine production saw substantial gains. Moderna ($MRNA) stock surged over 300% from March to December 2020, and Pfizer ($PFE) saw a more modest but steady increase. This historical precedent demonstrates that government commitment to vaccine access and funding directly benefits vaccine manufacturers. Specific winners if this bill progresses include major vaccine manufacturers such as Pfizer ($PFE), Moderna ($MRNA), Johnson & Johnson ($JNJ), GlaxoSmithKline ($GSK), and AstraZeneca ($AZN). These companies have established vaccine portfolios and supply chains, making them primary beneficiaries of continued federal procurement. There are no clear losers among publicly traded companies, as the bill aims to maintain or increase federal spending on vaccines, not reduce it. This bill is currently in committee review. The next step involves committee hearings and potential amendments. If it passes committee, it will move to a floor vote in the House. The timeline for passage is uncertain but typically takes several months to over a year for bills of this nature. The referral to three major committees (Energy and Commerce, Ways and Means, and Education and Workforce) indicates a broad scope and potential for detailed scrutiny.